Federal Supply Schedule V797D70102

The Federal Supply Schedule contract (V797D70102) held by Vanda Pharmaceuticals Inc. (Vanda) is for the provision of pharmaceutical products, primarily the drug Hetlioz (tasimelteon), to the U.S. Department of Veterans Affairs (VA). Hetlioz is used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome, conditions that significantly impact many veterans. Vanda has consistently received delivery order contracts and Blanket Purchase Agreements (BPAs) from various VA facilities, including Veterans Integrated Service Networks (VISNs) 12, 16, 20, and 22, to supply Hetlioz. These awards, valued from approximately $20,000 to $162,000 per order, are placed against Vanda's Pharmaceuticals and Drugs GSA Schedule contract and are not designated as set-asides. The VA has also established a $3.07 million single-award BPA with Vanda to facilitate the streamlined procurement of Hetlioz for eligible veterans, reflecting the VA's reliance on Vanda as a key supplier of this specialized pharmaceutical.

The VA's contracting approach with Vanda demonstrates the agency's recognition of the critical need for Hetlioz among its patient population and Vanda's ability to reliably fulfill these requirements. The delivery orders and BPAs ensure a steady supply of the medication to VA facilities across the country, enhancing the VA's capacity to address sleep disorders and improve the quality of life for the veterans it serves.